Utama › Kanser Hati (Karsinoma Hepatoselular) › Tennessee
Kajian klinikal Kanser Hati (Karsinoma Hepatoselular) di Tennessee
14 kajian untuk Kanser Hati (Karsinoma Hepatoselular) sedang mencari peserta di lokasi di Tennessee.
Bandar di Tennessee
Teks kajian rasmi (Bahasa Inggeris)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #3, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07291076A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Scri Oncology Partners, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06427941Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05919264A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- St. Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 19 Mei 2026 · NCT05468359Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- The West Clinic, Germantown
- University of Tennessee Medical Center, Knoxville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Apr 2026 · NCT05733598Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- HCA Research Institute, LLC, Brentwood
Mengambil pesertaFasa 1
Umur 18 hingga 65 · Semua jantina · Dikemas kini 16 Mac 2026 · NCT07176650A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
- University of Tennessee Medical Center, Knoxville
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Sep 2018 · NCT03686709Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.